Seattle -- The ARVO 2024 Annual Meeting was held from May 5th to 9th at the Seattle Convention Center in the United States. This prestigious event brought together over 11,000 ophthalmic scientists from more than 70 countries, featuring over 150 poster sessions and 100 paper sessions to showcase the latest global advancements in vision research and explore future directions in the field. 

TriApex was thrilled to showcase pivotal scientific posters featuring cutting-edge ophthalmology research at 2024 ARVO and the exhibition. Led by our team of ophthalmological scientists, TriApex actively participated in the event, engaging in profound discussions, and fostering valuable connections with industry experts and peers. On May 6^th and 7^th, amidst this prestigious gathering of international experts, TriApex presented three posters highlighting advantaged research in glaucoma, cataract and dAMD NHP disease models and our featured technological advancements.

On May 6th, TriApex unveiled the findings of earlier NHP glaucoma disease model. Laser photocoagulation of trabecular meshwork was performed to induce high ocular pressure in unilateral eye of Cynomolgus monkeys. Through the observations of IOP, vessel density and RNFLt, as well as the complete correlations and non-parametric tests, vessel density decline was founded to appear earlier than the onset of retinal nerve fiber atrophy in monkey Glaucoma models. Meanwhile, the presentation illustrate TriApex’s wealth experience in meticulous ophthalmic manipulation, professional animal care and state-of-the-art instruments.

Continuing the momentum on May 7^th morning, TriApex showcased the poster Incidence and types of spontaneous cataracts in an aged non-human primate population. A total of 301 aged Cynomolgus monkeys were underwent cataract screening. Cataract grades were scored and assessed by cogitative methods and standards. Four types of cataracts were identified in early developmental stages within the aged monkey population. These monkey cataracts represent a promising translatable disease model for studying the molecular mechanisms of cataracts and for pioneering innovative cataract drugs, which garnered keen interest from cataract disease experts and researchers.

Additionally, a well-received poster titled with Optimization of the Dry Age-related Macular Degeneration Model in Cynomolgus Monkeys by Intravitreal Injection of Sodium Iodate (SI) was presented on May 7^th afternoon. This study aimed to optimize the SI induced dAMD models in NHPs through managing the injection location and speed.

TriApex’s professional ophthalmic technicians performed meticulous intravitreal administration in monkeys with a timely manner. Series of complex and complete ophthalmic examination were conducted through precise equipment, including fundus photography (FP), optical coherence tomography (OCT), fluorescein fundus angiography (FFA), electroretinography (ERG) and fundus auto-fluorescence (FAF) and adaptive optics scanning laser ophthalmoscope (AOSLO).

Contributing to scientific modeling methods, a dry AMD model was successfully and stably established in Cynomolgus monkeys by intravitreal Sl injection. This model’s symptom is similar to that observed in human dry AMD patients. It can be used in the research and development of new drugs as part of pharmacodynamic studies. TriApex’s achievements captivated the attention of numerous academic and industrial researchers, fostering a vibrant environment for scientific exchange.

TriApex’s each poster presentation underscored the team’s innovative approach and scientific rigor in addressing critical challenges in ophthalmology, and showcased our extensive animal model resources and preclinical service capabilities. TriApex's participation at ARVO 2024 reaffirms its leadership in ophthalmic research and development. If you are interested in any content above or want to know additional information please visit www.tri-apex.com or contact us through BD@tri-apex.com.